29 October 2024
Rare Disease
Ipsen’s work in rare diseases currently focuses on how we can address areas of high unmet need for people affected by hormone and metabolic imbalances and rare liver disorders. We strive to understand the challenges faced by those living with rare diseas...
16 October 2024
Home
Working with leading clinical centres across the U.K. & Ireland, Ipsen’s research focuses on oncology, neuroscience and rare diseases, investigating new compounds and increasing understanding of our licensed medicines....
-
25 June 2026
U.K. MHRA grants marketing authorisation for Ipsen’s Bylvay® (odevixibat) for cholestatic pruritus in Alagille syndrome, a rare liver disease
LONDON, U.K., 25 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Bylvay® (odevixibat) a new indication for the ...
-
29 October 2024
Ipsen in Ireland
Ipsen has been present in Ireland since 1989, pioneering innovation across manufacturing, R&D and commercial activities at its site in Blanchardstown, Dublin. Ipsen Ireland employs approximately 190 staff in Ireland, including a team of over 20 chemist...
-
29 October 2024
Our Standards
This statement is made in accordance with section 54 of the Modern Slavery Act 2015, on behalf of the Ipsen companies operating and carrying on business within the U.K. (“Ipsen U.K.”). It sets out the steps that Ipsen U.K. has taken and is continuing t...